Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Help Diabetic Neuropathy?

A records study found fewer foot ulcers and more Charcot diagnoses. Direct research on whether GLP-1 drugs improve nerve function remains limited.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read
One-year rates — GLP-1 above, DPP-4 belowfoot ulcer2.2% / 2.7%amputation0.5% / 0.5%osteomyelitis0.4% / 0.4%Charcot foot0.3% / 0.2%19,770 matched patients per group, all with diabetic neuropathy.

Studies of walking ability in peripheral artery disease answer a different question from whether a GLP-1 drug can repair nerves affected by diabetes. The largest neuropathy study discussed here tracked foot complications in health records. Smaller studies evaluated nerve function and pain directly.

What the foot complication study found

Researchers matched 19,770 adults with type 2 diabetes and neuropathy starting a GLP-1 receptor agonist to 19,770 starting a DPP-4 inhibitor. At one year, a foot ulcer had been recorded for 2.2% versus 2.7%, a difference of about five per 1,000 people (hazard ratio 0.813, 95% CI 0.716 to 0.922) [1].

Charcot neuroarthropathy, which damages bones and joints in a foot with reduced sensation, was recorded in 0.3% versus 0.2%, a difference of roughly one per 1,000 based on the rounded rates. The hazard ratio was 1.993 (95% CI 1.297 to 3.064). Amputation and bone infection rates were similar in both groups. This observational study did not measure nerve function or show whether the drugs caused the differences.

Do GLP-1 drugs improve nerve function?

In a small, open-label randomized trial of 46 adults with type 2 diabetes and mild to moderate neuropathy, 18 months of exenatide showed no statistically significant advantage over insulin glargine on measured neuropathy outcomes, including nerve conduction and nerve fiber density[2].

A 2026 cross-sectional study evaluated 500 adults with type 2 diabetes. It found painful neuropathy in 10.1% of people already taking a GLP-1 drug versus 35.1% of those on standard treatment and 28.3% of those taking an SGLT2 inhibitor [3]. Because the researchers assessed the groups at one point in time, they could not tell whether the medication came before the difference in symptoms or whether treatment improved anyone’s nerve function.

Frequently asked

Do GLP-1 drugs reverse diabetic neuropathy?
That has not been established. A small randomized exenatide trial found no clear improvement in nerve measures over insulin glargine. The larger records study measured foot complications instead of nerve function.
What did the study find about Charcot foot?
Charcot neuroarthropathy was recorded in 0.3% of patients starting a GLP-1 drug and 0.2% of matched patients starting a DPP-4 inhibitor. The study cannot establish what caused the difference.

Sources

  1. [1] Tawfik F, et al. (2026). GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes Journal of Neurology. PMID 42704495
  2. [2] Jaiswal M, et al. (2015). Effects of Exenatide on Measures of Diabetic Neuropathy in Subjects with Type 2 Diabetes: Results from an 18-Month Proof-of-Concept Open-Label Randomized Study Journal of Diabetes and Its Complications. Source
  3. [3] Falco P, et al. (2026). Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes Pain. PMID 42663556
  4. [4] American Diabetes Association Professional Practice Committee (2026). Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes Diabetes Care. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence